Hepatitis C virus (HCV) infection is prevalent in Taiwan. Prof Ming-Lung Yu and his colleagues find that the HCV prevalence rate is as high as 30%-67% in certain villages located at southwestern costal of Taiwan. It is extremely a very criticalnational healthy issue since it is assumed that around 554,361 people are currently infected with HCV in Taiwan by Yu’s study.Yu et al. dedicate their research on HCV-related diseases, especially HCV virology, molecular epidemiology, pathogenesis, immunogenetics, clinical outcome, extrahepatic manifestations, treatment efficacy, factors associated with efficacy, improvement in the treatment efficacy and long-term outcome of HCV infection. The achievements of serial HCV studies by Yu et al., through improvement of treatment efficacy to translational studies on “personalized therapy” and precision medicine of “resource-guided therapy” for chronic hepatitis C, have been referenced as guidance of HCV management by European Association for the Study of the Liver (EASL), Asian Pacific Association for the Study of the Liver (APASL), Taiwan Association for the Study of the Liver (TASL) and National Health Insurance Administration, Ministry of Health and Welfare, Executive Yuan, Taiwan.

1. National Leader, Taiwan Clinical Trial Consortium for Liver Diseases -Successful conduction of several investigator-initiated trials -Efficient facilitation of many international and domestic multi-center clinical trials sponsored by pharmaceutical companies 2. Principal investigator, A Phase 3b Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects with Chronic Genotype 1 or 2 Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) Coinfection Achievements: -Confirm that HBV co-infection does not impact HCV SVR after DAA therapy -Prove that ledipasvir/sofosbuvir is effective for the treatment of HCV genotype 2 -Clarify risk and profile of HBV reactivation during and after DAA therapy Clinical impacts: -Lead to approval of ledipasvir/sofosbuvir for the treatment of HCV genotype 2 in many countries including Taiwan. The speed toward eradication of HCV infection in Taiwan national project before 2025 is facilitated. -The sponsor had very good profit after this new indication for HCV genotype 2, which is prevalent in Asia-Pacific region. -The safety of patients with HBV/HCV coinfection is improved due to the clarification of the risk of HBV reactivation. 3. National leader: The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis Achievements: Integrate Taiwan sites and facilitate recruitment of suitable subjects 4. President, 2022 APASL Single Topic Conference on HCC (Asia-Pacific international conference) 5. Associate editor, Liver International, Journal of the Formosan Medical Association, Journal of Microbiology, Immunolo and Infection 6 World's Top 2% Scientists, Stanford University statistics 2020

1. Great contribution to DAA drug development for HCV 2. Early phase drug development for HBV treatment 3. Early phase drug development for HCC treatment 4. Early phase drug development for NASH treatment

1. Great contribution to the treatment of Helicobacter pylori and gastric cancer prevention 2. Involved in the Taipei global consensus for gastric cancer prevention (Gut 2020;69:2093-2112) 3. Chair of the Asian Pacific Alliance on Helicobacter and Microbiota (APAHAM) 4. Global leading PI (Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial, clarithromycin, amoxicillin, metronidazole, lansoprazole) 5. Global leading PI (Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial, bismuth (KCB), clarithromycin, amoxicillin, metronidazole, lansoprazole)

Cold Versus Hot Snare Polypectomy for Small Colorectal Polyps: A Pragmatic Randomized Controlled Trial. (Ann Intern Med. 2023 Mar;176(3):311-319.) Linked-Color Imaging Detects More Colorectal Adenoma and Serrated Lesions: An International Randomized Controlled Trial. (Clin Gastroenterol Hepatol. 2023 Jun;21(6):1493-1502.) Optimal surveillance interval after piecemeal endoscopic mucosal resection for large colorectal neoplasia: a multicenter randomized controlled trial. (Surg Endosc. 2022 Jan;36(1):515-525.) Two vs One Forward View Examination of Right Colon on Adenoma Detection: An International Multicenter Randomized Trial. (Clin Gastroenterol Hepatol. 2022 Feb;20(2):372-380.) Controlled Dietary Restriction With a Prepackaged Low-Residue Diet Before Colonoscopy Offers Better-Quality Bowel Cleansing and Allows the Use of a Smaller Volume of Purgatives: A Randomized Multicenter Trial. (Dis Colon Rectum. 2016 Oct;59(10):975-83.) Carbon dioxide insufflation can significantly reduce toilet use after colonoscopy: a double-blind randomized controlled trial. (Endoscopy. 2014 Mar;46(3):190-5.) The impact of colon preparation timing on colonoscopic detection of colorectal neoplasms--a prospective endoscopist-blinded randomized trial. (Am J Gastroenterol. 2006 Dec;101(12):2719-25.)

1. Great contribution to the treatment of Helicobacter pylori and gastric cancer prevention 2. Involved in the Taipei global consensus for gastric cancer prevention (Gut 2020;69:2093-2112) 3. Secretary General of the Asian Pacific Alliance on Helicobacter and Microbiota (APAHAM) 4. Steering committee member (Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial, clarithromycin, amoxicillin, metronidazole, lansoprazole) 5. Global leading PI (Comparison of vonoprazan-based versus lansoprazole-based triple therapy, high dose dual therapy, bismuth and non-bismuth quadruple therapy in the first-line treatment of Helicobacter pylori infection -a multicenter, open labelled,randomized pilot trial, vonoprazan, lansoprazole)

To design the digestive tract cancer prevention programs by answering the questions about whether the specific cancer is preventable and if so, how to implement the program. To serve as the principle investigator of Taiwan Clinical Trial Consortium in Gastrointestinal Diseases & Helicobacter and innovated a series of effective eradication treatments using the design of multicenter, randomized controlled trials to through the cooperation of pharmaceutical companies. To initiate the clinical trial with mass screening of colorectal cancer and stomach cancer using fecal immunochemical testing and H. pylori stool antigen testing concurrently, called the “two-in-one” test, as a new product as the basis of a healthcare policy. To evaluate the performance of the conventional biomarkers and to identify the novel marker in the real-world setting and collaborate with the international academic centers, aiming to provide the new method for risk assessment for digestive tract cancers. To serve as the panelist for the global consensus meetings and working group reports for the stomach cancer prevention.